The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has captivated the globe's attention since its emergence in 2019. This highly …

The emergence of COVID-19 has posed an unprecedented global health crisis, challenging
the healthcare systems worldwide. Amidst the rapid development of several vaccine …

Due to waning immunity following primary immunization with COVID-19 vaccines, booster
doses may be required. The present study assessed a heterologous booster of SII-NVX …

Importance Immunological response to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) vaccination is important, especially in people with multiple sclerosis (pwMS) …

Abstract Background Bio Farma has developed a recombinant protein subunit vaccine
(IndoVac) that is indicated for active immunization in population of all ages. This article …

Importance The recombinant COVID-19 vaccine NVX-CoV2373 has demonstrated efficacy
of approximately 90% in adults; however, its safety and efficacy in children is unknown …

Neutralizing antibody responses from COVID-19 vaccines are pivotal in conferring
protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Effective …

In this phase III, open label, single arm, multicenter clinical study, we report safety,
tolerability and immunogenicity of PHH-1V as a booster dose in subjects primary vaccinated …

Objective: This study sought to assess the prevalence of adverse events following
immunization (AEFI) and factors associated with AEFI of the ChAdOx1 nCoV-19 vaccine …

Background A recombinant, adjuvanted COVID-19 vaccine, SII-NVX-CoV2373 was
manufactured in India and evaluated in Indian children and adolescents to assess safety …